RT Journal Article
SR Electronic
T1 Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.08.31.458247
DO 10.1101/2021.08.31.458247
A1 Paulina Kaplonek
A1 Deniz Cizmeci
A1 Stephanie Fischinger
A1 Ai-ris Collier
A1 Todd Suscovich
A1 Caitlyn Linde
A1 Thomas Broge
A1 Colin Mann
A1 Fatima Amanat
A1 Diana Dayal
A1 Justin Rhee
A1 Michael de St. Aubin
A1 Eric J. Nilles
A1 Elon R. Musk
A1 Anil S. Menon
A1 Erica Ollmann Saphire
A1 Florian Krammer
A1 Douglas A. Lauffenburger
A1 Dan H. Barouch
A1 Galit Alter
YR 2021
UL http://biorxiv.org/content/early/2021/08/31/2021.08.31.458247.abstract
AB The successful development of several COVID-19 vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed. However, in the wake of the emergence of viral variants, able to evade vaccine induced neutralizing antibodies, real world vaccine efficacy has begun to show differences across the mRNA platforms, suggesting that subtle variation in immune responses induced by the BNT162b2 and mRNA1273 vaccines may provide differential protection. Given our emerging appreciation for the importance of additional antibody functions, beyond neutralization, here we profiled the postboost binding and functional capacity of the humoral response induced by the BNT162b2 and mRNA-1273 in a cohort of hospital staff. Both vaccines induced robust humoral immune responses to WT SARS-CoV-2 and VOCs. However, differences emerged across epitopespecific responses, with higher RBD- and NTD-specific IgA, as well as functional antibodies (ADNP and ADNK) in mRNA-1273 vaccine recipients. Additionally, RBD-specific antibody depletion highlighted the different roles of non-RBD-specific antibody effector function induced across the mRNA vaccines, providing novel insights into potential differences in protective immunity generated across these vaccines in the setting of newly emerging VOCs.Competing Interest StatementG.A. is a founder and equity holder for Seromyx Systems Inc., an employee and equity holder for Leyden Labs, and has received financial support from Abbvie, BioNtech, GSK, Gilead, Merck, Moderna, Novartis, Pfizer, and Sanofi. D.D., J.R., A.S.M, and E.R.M. are employees of Space Exploration Technologies Corp. All other authors have declared that no conflict of interest exists.